Can endometriosis cause hair loss? It is a question many people living with this chronic condition find themselves asking, particularly when they notice increased shedding or thinning alongside their other symptoms. Whilst there is no officially established direct causal link, the hormonal disruption, chronic inflammation, nutritional deficiencies, and medical treatments associated with endometriosis can all contribute to hair changes. This article explores the biological mechanisms, treatment-related factors, and practical steps you can take to address hair loss when managing endometriosis.

How Endometriosis Affects Hormones and Hair Growth

Endometriosis is oestrogen-driven and causes chronic inflammation, both of which may disrupt the hair growth cycle, though direct clinical evidence linking these mechanisms to hair loss in endometriosis specifically remains limited.

Not sure if this is normal? Chat with one of our pharmacists →

Endometriosis is a chronic inflammatory condition in which tissue similar to the uterine lining grows outside the womb, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. One of its defining features is its hormone-dependent nature — endometriosis lesions are driven primarily by oestrogen, which stimulates their growth and survival (NICE NG73). This hormonal dependency means that the condition can disrupt the broader endocrine environment, with potential knock-on effects throughout the body, including on hair follicle health.

Hair growth follows a cyclical process — the anagen (growth), catagen (transition), and telogen (resting and shedding) phases — and is sensitive to hormonal fluctuations. Oestrogen is thought to support the anagen phase in some contexts, though the relationship between oestrogen and hair growth in humans is complex and not fully established. Androgens, particularly dihydrotestosterone (DHT), can miniaturise hair follicles in genetically susceptible individuals, leading to thinning. It is important to note that elevated androgens are not a recognised feature of endometriosis itself; if androgen excess is suspected, this should prompt assessment for other conditions such as polycystic ovary syndrome (PCOS) rather than being attributed to endometriosis.

Chronic inflammation — a hallmark of endometriosis — may also influence hair follicle function. Inflammatory cytokines have been proposed in research settings to interfere with the anagen phase and promote premature entry into telogen, potentially contributing to diffuse hair shedding. However, direct clinical evidence for this mechanism in people with endometriosis specifically remains limited. The hormonal and inflammatory burden of endometriosis provides a plausible, though not proven, biological basis for hair changes in some individuals, and these mechanisms should be understood as hypotheses rather than established causal pathways.

The Link Between Endometriosis and Hair Loss

There is no officially established causal link between endometriosis and hair loss; the relationship is likely indirect, mediated through hormonal imbalance, nutritional deficiencies, psychological stress, and treatment side effects.

Experiencing these side effects? Our pharmacists can help you navigate them →

Many people living with endometriosis report experiencing hair thinning or increased shedding, and this is an area of growing clinical interest. However, it is important to note that there is currently no officially established causal link between endometriosis itself and hair loss as a direct symptom. The relationship is likely indirect, mediated through hormonal imbalance, nutritional deficiencies, psychological stress, and the side effects of treatments used to manage the condition.

One proposed hormonal mechanism involves relative progesterone resistance, which is recognised in endometriosis — meaning that even when progesterone levels appear adequate, the body's tissues may not respond normally (NICE NG73). Some researchers have suggested this could theoretically influence hair follicle sensitivity, though direct clinical evidence linking progesterone resistance in endometriosis to hair loss is limited, and this should be understood as a hypothesis rather than an established mechanism.

Telogen effluvium — a form of diffuse, temporary hair shedding triggered by physiological stress — is another plausible mechanism. The chronic pain, immune dysregulation, and systemic inflammation associated with endometriosis can act as ongoing stressors that push a greater proportion of hair follicles into the telogen phase simultaneously, resulting in noticeable shedding typically two to four months after the triggering event (PCDS: Telogen effluvium).

Nutritional deficiencies can further compound hair shedding. Iron deficiency is the most strongly evidenced nutritional contributor to hair loss and is particularly relevant in those who experience heavy menstrual bleeding. It should be noted that heavy periods are not universal in endometriosis and are more commonly associated with adenomyosis or uterine fibroids; however, some people with endometriosis do experience heavier bleeding (NICE NG88). Deficiencies in vitamin D and zinc have also been associated with hair shedding in observational studies, though the evidence for a direct causal role is less robust than for iron.

Other Causes of Hair Loss to Consider

Thyroid dysfunction, PCOS, iron deficiency anaemia, and alopecia areata are key differential diagnoses that must be excluded through blood tests and clinical assessment before attributing hair loss to endometriosis.

When assessing hair loss in someone with endometriosis, it is essential not to attribute all symptoms automatically to the condition. Several other causes of hair loss are common in women of reproductive age and may occur independently or alongside endometriosis.

Key differential diagnoses include:

• Thyroid dysfunction — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning and are more prevalent in women with autoimmune or inflammatory conditions

• Polycystic ovary syndrome (PCOS) — which can co-exist with endometriosis and is associated with elevated androgens causing hair thinning at the crown and temples

• Iron deficiency anaemia — particularly relevant in those with heavy periods; iron deficiency is the most strongly evidenced nutritional cause of hair shedding

• Alopecia areata — an autoimmune condition causing patchy hair loss, which may be more prevalent in individuals with other immune-mediated conditions

• Nutritional deficiencies — low levels of ferritin, vitamin B12, or vitamin D may contribute to hair shedding, though evidence varies in strength

• Psychological stress and anxiety — highly prevalent in those managing chronic pain conditions and a recognised trigger for telogen effluvium

It is also worth considering that some hair loss may be entirely unrelated to endometriosis and simply coincidental. A thorough clinical assessment, including targeted blood tests and a detailed medical history, is necessary to identify the underlying cause or causes. NICE CKS and the Primary Care Dermatology Society (PCDS) recommend a structured approach to investigating hair loss in women, which includes ruling out systemic and endocrine causes. Testing for androgens or prolactin is generally recommended only when there are clinical features suggesting excess, such as hirsutism, acne, or menstrual irregularity, rather than as a routine screen.

Red flags that should prompt early dermatology referral include features suggesting scarring alopecia (such as follicular inflammation, skin atrophy, or permanent bald patches) or signs of tinea capitis (scalp scaling with broken hairs), as these require specialist assessment and management.

Treatments for Endometriosis That May Affect Hair

GnRH analogues and progestogens with high androgenic activity are the endometriosis treatments most likely to contribute to hair thinning; switching formulations or adding add-back therapy can help mitigate this.

Several medical treatments used to manage endometriosis can themselves influence hair growth and contribute to hair loss, making it important to consider treatment-related causes when evaluating this symptom.

Hormonal therapies are the cornerstone of endometriosis management (NICE NG73) and include:

• Combined oral contraceptive pill (COCP) — generally considered hair-neutral or mildly protective, though some progestogens with higher androgenic activity (e.g., levonorgestrel, norethisterone) may worsen hair thinning in susceptible individuals. Formulations containing less androgenic progestogens (e.g., drospirenone, desogestrel) may be preferable in this context (FSRH guidance on combined hormonal contraception).

• Progestogen-only treatments — such as the desogestrel pill or the levonorgestrel intrauterine system (Mirena), may affect hair differently depending on their androgenic profile. The levonorgestrel IUS delivers hormone locally with low systemic absorption, which may limit systemic androgenic effects (MHRA/EMC SmPC: Mirena).

• GnRH analogues (e.g., goserelin, leuprorelin) — these induce a temporary, medically managed menopause by suppressing ovarian oestrogen production. The resulting low-oestrogen state can trigger telogen effluvium and hair thinning, which is usually reversible upon cessation of treatment (MHRA/EMC SmPCs: Zoladex, Prostap). In line with NICE NG73, GnRH analogues are typically prescribed alongside add-back hormonal therapy (such as a low-dose oestrogen and progestogen combination) to mitigate hypo-oestrogenic adverse effects, including potential effects on hair.

• Danazol — an older androgenic agent now rarely used due to its side effect profile, which includes significant hair thinning and hirsutism (MHRA/EMC SmPC: Danazol). It is not recommended as a first-line treatment.

Understanding which treatment may be contributing to hair changes allows clinicians and patients to make informed decisions about adjusting therapy. Any concerns about hair loss related to prescribed medication should be discussed with a GP or gynaecologist before stopping treatment, as abrupt discontinuation may worsen endometriosis symptoms. If you suspect a medicine is causing a side effect, you can report this to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Managing Hair Loss Alongside Endometriosis

Managing hair loss with endometriosis involves correcting nutritional deficiencies, reviewing hormonal therapy, and addressing stress; topical minoxidil is UK-licensed for confirmed female pattern hair loss.

Managing hair loss in the context of endometriosis requires a holistic approach that addresses both the underlying hormonal environment and any contributing nutritional or lifestyle factors. The first step is identifying and treating any correctable causes, such as iron deficiency or thyroid dysfunction, through appropriate blood tests and supplementation where indicated.

Practical steps that may help include:

• Treating confirmed iron deficiency — iron deficiency is the most strongly evidenced nutritional cause of hair shedding. Treatment should be guided by blood results and discussed with a GP (NICE CKS: Iron deficiency anaemia). Some dermatology specialists (PCDS) suggest that ferritin levels in the lower end of the normal range may still be suboptimal for hair growth, though a specific threshold (such as 70 µg/L) is not an NHS or NICE standard, and the evidence base for this figure is limited; supplementation should be based on confirmed deficiency or clinical judgement.

• Correcting vitamin D deficiency — deficiency is common in the UK population and has been associated with hair follicle cycling in observational studies. Supplementation is recommended to correct confirmed deficiency; evidence that it directly improves hair regrowth is limited.

• Reviewing hormonal therapy — switching to a contraceptive or hormonal treatment with a lower androgenic progestogen profile may reduce hair thinning in some individuals; this should be discussed with a GP or gynaecologist.

• Stress management — techniques such as mindfulness, cognitive behavioural therapy (CBT), and regular gentle exercise may help reduce the physiological stress burden that contributes to telogen effluvium.

• Scalp and hair care — avoiding excessive heat styling, tight hairstyles, and harsh chemical treatments can minimise mechanical hair loss.

In cases of confirmed female pattern hair loss (androgenetic alopecia), topical minoxidil is licensed in the UK for this indication and is available over the counter (MHRA/EMC SmPC: Regaine for Women). It can slow progression and promote regrowth, though it is unlikely to benefit hair loss from other causes such as telogen effluvium. Minoxidil should not be used during pregnancy or breastfeeding; consult the product information or a pharmacist for full precautions. Hair loss treatments typically take several months to show effect, and patience is an important part of management.

Anti-androgen medications such as spironolactone are sometimes considered for female pattern hair loss in specialist settings. It is important to be aware that spironolactone is not licensed for hair loss in the UK and its use for this purpose is off-label. It requires effective contraception (as it is teratogenic), regular monitoring of renal function and potassium levels, and should only be initiated and supervised by an appropriate specialist (BNF: Spironolactone).

When to Speak to Your GP or Specialist

See your GP promptly if you experience sudden, patchy, or rapidly progressive hair loss, or if thinning coincides with starting a new hormonal treatment, as blood tests can identify treatable contributing causes.

Hair loss can be distressing, particularly when it occurs alongside the physical and emotional burden of a chronic condition such as endometriosis. Knowing when to seek medical advice is important to ensure timely investigation and appropriate support.

You should contact your GP if you notice:

• Sudden or rapidly progressive hair shedding

• Patchy hair loss or bald spots (which may suggest alopecia areata)

• Hair loss accompanied by other symptoms such as fatigue, weight changes, or feeling unusually cold or warm (which may indicate thyroid dysfunction)

• Hair thinning that begins or worsens after starting a new hormonal treatment

• Significant scalp changes, including redness, scaling, or scarring

• New or worsening hirsutism (unwanted hair growth), acne, or other signs of androgen excess, which should prompt assessment for conditions such as PCOS

Your GP can arrange initial blood tests to help identify contributing factors. Typical first-line investigations include a full blood count, ferritin, thyroid function tests (TSH), and vitamin B12 and vitamin D if clinically indicated (NICE CKS: Assessment of hair loss). Testing for androgens or prolactin is generally reserved for those with clinical features suggesting excess, such as hirsutism, acne, or menstrual irregularity, rather than being performed routinely.

If a dermatological or endocrine cause is suspected, referral to a dermatologist or endocrinologist may be appropriate. For those whose hair loss appears linked to their endometriosis management, a review with a gynaecologist or specialist endometriosis service is advisable. Specialist endometriosis centres commissioned by NHS England are listed through the British Society for Gynaecological Endoscopy (BSGE) and can provide expert multidisciplinary care.

It is also worth raising hair concerns at routine endometriosis reviews, as they may influence treatment decisions. Open communication with your healthcare team ensures that both your endometriosis and its wider effects on your health and wellbeing are managed in a joined-up, patient-centred way. Hair loss is a legitimate symptom that deserves proper clinical attention.

Frequently Asked Questions